[ASCO-GI 2015]胃肠癌症病例管理及转化医学研究进展 ——Paul Mansfield博士专访

作者:肿瘤瞭望   日期:2015/1/17 18:41:23  浏览量:83434

肿瘤瞭望版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

2015胃肠癌症研讨会的亮点包括3个主题演讲、上消化道癌症疑难病例的管理、转化研究等部分。在1月15日下午“上消化道癌症疑难病例管理”板块,德克萨斯大学MD安德森癌症中心的Paul Mansfield博士从外科学角度,探讨了上消化道癌症管理的问题。《肿瘤瞭望》前方记者就“胃肠道癌症管理和转化医学问题”现场采访了Mansfield博士。

 Oncology FrontierIn your observations of the markers and databases, have you noticed any ethnic trends, and more specifically, can you discuss Asian populations and the incidence of gastrointestinal cancer?

 

  《肿瘤瞭望》:根据您的数据库的记载,胃肠癌症的发病有无种族特征,能否谈一谈亚洲人的胃肠道癌发病率和预测治疗疗效的标志物?

 

  Dr Mansfield: In Asian countries, the incidence of gastric cancer is many-fold higher than it is in the United States. As a matter of fact, it is an interesting dynamic that in the US, gastric cancer used to be the most common type of cancer similar to how it is in China, Korea and Japan. But sixty or so years ago, the incidence dramatically began to drop. There are many reasons including cultural, dietary and food preservation issues that appear to have had some impact. So it is a very common disease in those countries. There are some differences as far as responsiveness to certain types of chemotherapy based on differences in body metabolism with genetic correlations. Chemotherapy such as S1 is much more likely to work in an Asian patient than in a Caucasian patient.

 

  Mansfield博士:亚洲国家的胃癌发病率是美国的好几倍。虽然胃癌曾经也是美国的常见癌种,但60多年来美国的胃癌发病急剧下降,其原因是多方面的,包括文化、饮食和食物保鲜的问题。由于遗传相关的体内新陈代谢的差异,亚洲人和白种人在对化疗方案的响应方面有差异,比如S-1化疗方案适于亚洲患者。

上一页  [1]  [2]  [3]  [4]  下一页

版面编辑:张楠  责任编辑:张彩琴

本内容仅供医学专业人士参考


癌症转化医学胃癌患者化疗方案2015胃肠癌症研讨会

分享到: 更多